Ionis hit by safety concerns, rivals Alnylam benefit
Biotech insists drug for rare inherited disorder is still approvable.
X
Ionis hit by safety concerns, rivals Alnylam benefit
https://pharmaphorum.com/news/ionis-inotersen-meets-efficacy-targets-fap-safety-concerns-spook-investors/
